Severe symptomatic hypocalcaemia following a single dose of denosumab

Medical Journal of Australia

Volumn 199, Issue 4, 2013, Pages 242-243

  McLachlan, Jennifer M ^a   Marx, Gavin M ^a   Bridgman, Margaret ^a  

^a SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; COLECALCIFEROL; DENOSUMAB; GLUCONATE CALCIUM;

AGED; BREAST METASTASIS; CALCIUM BLOOD LEVEL; CARPOPEDAL SPASM; CASE REPORT; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPOCALCEMIA; LETTER; MUSCLE SPASM; PARESTHESIA; PERIORAL PARAESTHESIA; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; TETANY; VITAMIN BLOOD LEVEL;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOCALCEMIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84882287315     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10038     Document Type: Letter

References (5)

1. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
2. Stopeck AT, Lipton A, Body J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
3. Autio KA, Farooki A, Glezerman I, et al. Risk assessment for severe hypocalcemia requiring hospitalisation with denosumab [abstract]. J Clin Oncol 2013; 31 Suppl 6: abstr 115.
4. Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479.
5. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008; 336: 1298.